FY2026 · ended Mar 31, 2026 · Revenue $16.00M, +16.0% YoY · Filed Jul 14, 2026
Biotricity Inc. (BTCY) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $16.0 million and a net loss of $2.4 million. As of Jun 30, 2026 it held $466,503 in cash and investments and $252,172 in total debt.
Revenue (TTM)
$16.40M
+13.4% vs year-ago TTM
Net income (TTM)
$-2.69M
+50.1% vs year-ago TTM
Operating cash flow (TTM)
$161,661
+112.8% vs year-ago TTM
Free cash flow
$-15.19M
EPS (TTM)
$-0.13
+44.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
20.07M
-24.4% vs prior year
Net cash
$214,331
as of Jun 30, 2026
Operating margin
9.6%
FY 2027
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BTCY (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- Redwood City, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1630113
- Former names
- METASOLUTIONS, INC. (until Jan 5, 2016)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $16.0M | $13.8M | $12.1M | $9.6M | $7.7M |
| Operating income | $1.7M | -$2.4M | -$8.8M | -$15.4M | — |
| Net income | -$2.4M | -$8.4M | -$14.1M | -$18.7M | -$29.1M |
| Diluted EPS | -$0.12 | -$0.56 | -$1.66 | — | — |
| Operating cash flow | -$718,955 | -$2.4M | -$6.7M | -$13.5M | -$15.2M |
| Free cash flow | — | — | — | — | -$15.2M |
| Total assets | $6.4M | $5.6M | $5.9M | $6.5M | $16.7M |
| Total liabilities | $39.4M | $35.7M | $35.9M | $26.4M | $18.8M |
| Stockholders' equity | -$34.7M | -$32.0M | -$31.5M | -$19.8M | -$2.1M |
| Cash and investments | $149,789 | $365,145 | $786,060 | $570,460 | $12.1M |
| Total debt | $397,830 | $929,116 | $1.4M | $1.7M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 28, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Jul 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
|
May 1, 2026 | May 1, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 18, 2026 | Feb 11, 2026 |
| 10-Q | Quarterly report | Feb 11, 2026 | Dec 31, 2025 |
All 317 Biotricity Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.